CML-CAB Progress Card



CAB Slides 72020 10 05 Slides 9

CML-CAB History



From History to Present:

2020 10 05 Slides 2


Based on the proven ECAB model implemented by the HIV patient community and EATG for more than a decade, the first CML-CAB was held in May 2016. Since then, we have carried out 11 CML-CABs in 21 sessions (2016-2020).






Academic CMLCAB

In October 2020, we will hold our first Academic CML-CAB with 8 scientific experts working on novel areas of CML research. Click here to find out more!

How does the CML-CAB work?



CML-CAB meetings, are community-run advisory boards where the patient community decides on the topics of highest relevance and impact for the patient community. External stakeholders attending the CAB meeting can make suggestions for agenda points, but the final decision on the agenda rests with the CML-CAB chairs who decide in the interest of the community.

Participants of the CML-CAB meetings have the opportunity of a two-way dialogue discussing key topics in CML between key leading advocates of the patient community and external stakeholders. In each CML-CAB follow-up actions are identified. Follow-up of agreed action items is ensured through our “Actions Tracker” system where progress on action items is regularly monitored and documented. The outcome is reflected in a CML-CAB “Progress Card” that is presented at the following CML-CAB and shows CML-CAB´s assessment of progress since the last CML-CAB, companies´ involvement with the CML-CAB, and how we feel the CML-CAB advice was acted upon. 

Click here to see an example for a blank CML-CAB “Progress Card”.

CML-CAB operates under confidentiality, which is of paramount importance for the smooth and efficient functioning of CML-CAB. CML-CAB is a platform to discuss issues of highest relevance to both the patient community as well as the company in a two-way dialogue. Signing a Confidentiality Agreement is therefore a prerequisite for CML-CAB members´ participation.



Click here to see the  pdf CMLCAB Infographic (702 KB)  in detail.


CML-CAB composition



Pursuing its mission, CML-CAB builds on the work of expert patients who all speak from the unique perspective of a CML patient or relative. Altogether, CML-CAB members account for close to 250 hours of patient years. With that, CMLCAB can build upon an invaluable amount of CML experience!  

The CML-CAB is currently comprised of 2 chairs and 16 CML-CAB-members (as per October 2020) representing the 6 world regions. The CML-CAB is operationally supported by the CML-CAB Management Team.

2020 CAB team

Composition Nov2020

Members of the CML Advocates Network Steering Committee may additionally join CML-CAB meetings on the personal invitation of the chairs. 




CML-CAB participation



Participation in CML-CAB meetings

It falls within the responsibility of the CML-CAB chairs to determine how many and which members from the CML-CAB member pool (and potentially others) will be invited to specific CAB-meetings. The CML-CAB chairs will select participants based on their skills (identified in CML-CAB self-assessment survey established for this sole purpose) and the expertise and experience required for the particular meeting. The CML-CAB chairs’ choice shall reflect the expertise required for particular meeting to the best possible extend. In global CML-CAB meetings, the agreed minimum number of 8 participants (one representative of each region plus the two chairs) must not be undercut.




CML-CAB Objectives and Strategy



The CML-CAB objectives are:

  • Providing researchers, academics, government, policy makers, authorities and the pharmaceutical industry with advice and input on different issues that impact on patients’ lives 
  • Promoting best-in-class CML research as well as the harmonisation of good clinical practice, standard of care and access to best available CML therapies and diagnostic tools 
  • Ensuring patient needs are considered when setting research priorities
  • Developing patient-friendly clinical trials and helping interested patients access these
  • Addressing problems CML patients face in accessing optimal diagnosis, monitoring, treatment and care
  • Improving the outcomes of CML patients
  • Improving the quality of patient information and education
  • Building CML advocacy community capacity

Strategic priorities

2020 10 05 Slides 1


Please donate!

Please donate!


EU e-Privacy Directive